Fulcrum Therapeutics Net Income Over Time
| FULC Stock | USD 10.87 0.53 5.13% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Fulcrum Therapeutics Performance and Fulcrum Therapeutics Correlation. Will Pharmaceuticals sector continue expanding? Could Fulcrum diversify its offerings? Factors like these will boost the valuation of Fulcrum Therapeutics. Market participants price Fulcrum higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fulcrum Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fulcrum Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Fulcrum Therapeutics and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COR | (207.7 M) | 719 M | 433.7 M | 276.5 M | (134.9 M) | 1.4 B | 414.5 M | 1.7 B | 855.4 M | (3.4 B) | 1.5 B | 1.7 B | 1.7 B | 1.5 B | 1.6 B | 1.8 B | 1.9 B |
| REGN | (3.3 M) | (221.8 M) | 750.3 M | 424.4 M | 348.1 M | 636.1 M | 895.5 M | 1.2 B | 2.4 B | 2.1 B | 3.5 B | 8.1 B | 4.3 B | 4 B | 4.4 B | 4.5 B | 4.7 B |
| IDXX | 3.2 M | 161.8 M | 178.3 M | 187.8 M | 181.9 M | 192.1 M | 222 M | 263.1 M | 377 M | 427.7 M | 581.8 M | 744.8 M | 679.1 M | 845 M | 887.9 M | 1.1 B | 1.1 B |
| HLN | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 1.1 B | 1.4 B | 1.1 B | 1 B | 1.4 B | 1.7 B | 1.2 B |
| CI | (854.6 M) | 1.3 B | 1.6 B | 1.5 B | 2.1 B | 2.1 B | 1.9 B | 2.2 B | 2.6 B | 5.1 B | 8.5 B | 5.4 B | 6.7 B | 5.2 B | 3.4 B | 6 B | 6.3 B |
| ELV | 172.4 M | 2.6 B | 2.7 B | 2.7 B | 2.6 B | 2.6 B | 2.5 B | 3.8 B | 3.8 B | 4.8 B | 4.6 B | 6.1 B | 5.9 B | 6 B | 6 B | 5.7 B | 3.3 B |
| BDX | 88 M | 1.2 B | 1.3 B | 1.2 B | 695 M | 976 M | 1.1 B | 311 M | 1.2 B | 874 M | 2.1 B | 1.8 B | 1.5 B | 1.7 B | 1.7 B | 1.9 B | 2 B |
| ARGX | (4.5 M) | (4.5 M) | (12.8 M) | (8.5 M) | (12.5 M) | (16.7 M) | (22.5 M) | (33.7 M) | (76.2 M) | (181.2 M) | (608.5 M) | (407.6 M) | (709.6 M) | (295.1 M) | 833 M | 749.7 M | 787.2 M |
| TAK | 119.6 B | 124.2 B | 131.2 B | 106.7 B | (145.8 B) | 80.2 B | 114.9 B | 186.9 B | 109.1 B | 44.2 B | 376 B | 230.1 B | 317 B | 144.1 B | 107.9 B | 97.1 B | 155.3 B |
Fulcrum Therapeutics and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Fulcrum Therapeutics financial statement analysis. It represents the amount of money remaining after all of Fulcrum Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Fulcrum Therapeutics | FULC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 26 Landsdowne Street, |
| Exchange | NASDAQ Exchange |
USD 10.87
Check out Fulcrum Therapeutics Performance and Fulcrum Therapeutics Correlation. For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Fulcrum Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.